• Over 25 years of executive management in the life science industry; President of Cardioresponse, VP Coordinated Care Solutions, Managing Partner of Extera, Managing Director & Head Life Sciences at Armory Securities, Board Member of Janus Biotherapeutics, Atacama Therapeutics & Acer Therapeutics, and multiple corporate development roles with small to midsize life science companies. Jonathan earned his MD from the Technion Institute of Technology and his MBA from the Harvard Business School.

  • Neil has broad expertise in drug development, functional areas of business development, project management, regulatory affairs, and clinical project management and operations. As a Senior Director of External Innovation at Eli Lilly and Company, Neil was focused on venture capital backed investments into new company creation of project focused companies. Neil also held direct responsibilities for regulatory filings with major competent authorities globally, and for the design and oversight of early phase drug development programs, including phase 1 first-in-man clinical trials as part of Chorus, Eli Lilly’s virtual drug development engine. Prior to his current role at Censa, he was a Senior Director Project Management and Head BD with Flexion Therapeutics. Neil has a Doctor of Pharmacy degree from the University of Maryland Baltimore and a Master in Business Administration from the University of Baltimore.

  • Geoff joined Censa with 15+ years’ experience in regulatory affairs. He held senior positions in Regulatory and Quality with early-stage biotech, CROs and large pharma including Vice President of Global Medical & Regulatory Affairs with Cmed Clinical Services where he managed the regulatory affairs group, supported drug and device product development, gained global drug product clearances and approvals, and created regulatory market access strategies. He also served as an advisor to regulatory agencies throughout Europe and Asia-Pacific. Geoff received his B.Sc. in Cognitive Neuroscience from the University of Alabama and his MBA in Global Management from Regis University.

  • Michelle has over 25 years of clinical development experience in clinical operations and medical marketing. As Clinical Science Operations Project Leader and Director of Clinical Research with Genzyme/Sanofi, she has launched and directed global clinical operations activities from early development to submissions to regulatory authorities. Prior to Genzyme, Michelle monitored clinical activities at a clinical research organization and worked as a registered nurse in the acute care setting. Michelle has a Bachelor of Science Degree in Nursing and Biology from St. Mary’s, Notre Dame.

  • Eric has over 25 years of experience in the pharmaceutical, biotech and medical device industries across all phases of development, including commercial products.  As Associated Director of Quality in companies like Imugen, Axcella Health and First Light Biosciences, Eric has led the development and implementation of Quality Systems drawing on years of experience as an analytical chemist and leader of scientific teams.  Eric has an MS in Management from Lasell College and a BS in Biology from Millersville University of Pennsylvania.

  • Scott Reynolds PhD – CMC Planning and Oversight

    Former Associate Vice President, Formulation Sciences, Pharmaceutical Sciences and Clinical Supplies Merck Research Laboratories, Vice President, Chemical Process Development and Commercialization, Global Pharmaceutical Commercialization, Merck Manufacturing Division.

    Dan Levy PhD – Drug Substance

    Former Director of Synthetic Chemistry at Intradigm and a Medicinal Chemistry Group Leader at Scios.

    Anil Patel PhD – Drug Product

    Former Senior Product Development Director Shire Pharmaceutical, Vice President, Pharmaceutical & Analytical Development LifeCycle Pharma, Director, Pharmaceutical Development Janssen Pharmaceuticals.

  • Jeff has 25+ years of business and corporate development expertise; led or supported over 30 transactions with an aggregate value in excess of $1B across all major therapeutic platforms. Has orphan drug expertise. Currently a Partner at Extera Partners. Previously at Genzyme, Archemix, ImmunoGen, GenVec, and Eli Lilly.